-

Eurofins Covid Testing Services Ltd (ECTS) Supports Reopening UK Travel by Making PCR Testing Affordable for All

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Covid Testing Services Ltd (ECTS) recognises the importance of testing in the fight against COVID-19. Only the PCR test can provide the accuracy, reliability and variant tracking required to ensure the continued safety of everyone in the UK and whilst travelling.

ECTS wants to support the airline, travel and tourism industries and facilitate travel for all by removing the barrier of expensive testing. ECTS has therefore recently made significant investments in technology and automation to be able to drastically reduce the price of test-at-home PCR kits to just £44.90, providing the UK’s lowest cost option for both Test-To-Depart and Test-To-Release. Kits can be ordered direct from Eurofins at: https://www.eurofins.co.uk/pcr-testing-kits/test-to-release/

ECTS also provides faster turnaround time premium options with personal test delivery and pick-up by courier in London to reduce time to return the swabs to the laboratory for analysis and ensure a result within 24 hours or less. This service will shortly be made available in other large UK cities.

Before the summer travel season, ECTS will also be setting up multiple sampling locations for destinations in countries that require sampling by trained medical personnel or serology testing as well as convenient drop off locations to return samples to its laboratories and reduce time to results while keeping costs affordable.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

Group Investor Relations
ir@eurofins.com

Nick Phillips
E-mail: ir@eurofins.com

Eurofins

BOURSE:ERF

Release Versions

Contacts

Group Investor Relations
ir@eurofins.com

Nick Phillips
E-mail: ir@eurofins.com

More News From Eurofins

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 January 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedi (including the issuer ID allocated by the CSSF) EUROFINS SCIENTIFIC SE – E1013 2. Identi...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 02nd February to 06th February 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 02/02/2026 FR0014000MR3 10 000 68.3375 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 03/02/2026 FR0014000MR3 10 000 67.9091 XPAR EUROFINS SCIENTIFIC 529900JEHFM...

Eurofins Viracor BioPharma Expands Bioanalytical Capabilities

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical...
Back to Newsroom